Immix Biopharma grants CEO 500K stock options

Immix Biopharma, Inc. reported that CEO and Chairman Ilya M. Rachman received a grant of stock options covering 500,000 shares of common stock.

Rhea-AI Filing Summary

Immix Biopharma, Inc. reported that CEO and Chairman Ilya M. Rachman received a grant of stock options covering 500,000 shares of common stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036.

These options were granted as compensation and do not represent an open-market purchase or sale. According to the terms, they vest in 48 equal monthly installments following the grant date, contingent on Dr. Rachman’s continued service with the company.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider Rachman Ilya M

Role CEO and Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Key Figures

Options granted: 500,000 options Exercise price: $8.78 per share Underlying shares: 500,000 common shares +3 more

6 metrics

Options granted 500,000 options Stock Option (Right to Buy) granted to CEO on May 22, 2026

Exercise price $8.78 per share Conversion or exercise price of granted stock options

Underlying shares 500,000 common shares Shares of common stock underlying the stock options

Expiration date May 22, 2036 Option expiration for the CEO’s stock option grant

Vesting schedule 48 monthly installments Options vest in 48 equal monthly installments after grant date

Post-transaction options 500,000 options Total derivative securities held directly following the transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.7800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest in 48 equal monthly installments following the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-05-22T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immix Biopharma (IMMX) disclose about CEO Ilya Rachman’s latest equity grant?

Immix Biopharma reported a grant of stock options to CEO Ilya M. Rachman for 500,000 underlying common shares at an exercise price of $8.78 per share, expiring May 22, 2036, as part of his compensation package.

Is the Immix Biopharma (IMMX) CEO’s new Form 4 transaction a stock purchase or a grant?

The Form 4 shows a stock option grant, not an open-market purchase. CEO Ilya M. Rachman received options as compensation, with the right to buy 500,000 shares at $8.78 per share if he exercises them in the future.

How do the 500,000 Immix Biopharma (IMMX) stock options granted to the CEO vest?

The 500,000 stock options granted to CEO Ilya M. Rachman vest in 48 equal monthly installments after the grant date. Vesting depends on his continued service with Immix Biopharma, aligning the award with long-term employment and performance.

When do the Immix Biopharma (IMMX) CEO’s new stock options expire?

The granted stock options expire on May 22, 2036. Until that date, once vested, CEO Ilya M. Rachman can choose to exercise them at the fixed $8.78 per-share exercise price, subject to the plan’s terms and conditions.

How many Immix Biopharma (IMMX) options does the CEO hold after this Form 4 transaction?

After this transaction, CEO Ilya M. Rachman holds 500,000 stock options directly according to the filing. All of these options relate to common stock and carry the $8.78 exercise price disclosed in the Form 4 data.

Does the Immix Biopharma (IMMX) Form 4 indicate any option exercises or share sales by the CEO?

The Form 4 only reports a grant of stock options to the CEO. It does not show any option exercises, share sales, or open-market trades, and the transaction is coded as an award-type acquisition rather than a purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rachman Ilya M

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CALIFORNIA 90064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.78	05/22/2026		A		500,000		(1)	05/22/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Ilya M. Rachman	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)